PARP inhibitors for prostate cancer

Area of Science:

• Oncology
• Genetics

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) treatment has been significantly advanced by Poly(ADP-ribose) polymerase (PARP) inhibitors, particularly in patients with DNA damage response (DDR) gene alterations.
• The efficacy of PARP inhibitors has driven the adoption of comprehensive genomic testing for all mCRPC patients.

Approach:

• This review synthesizes current knowledge on the interaction between DNA damage response pathways and PARP enzymes.
• It examines the clinical applications of PARP inhibitors, including their combination with androgen-receptor signaling agents.
• The review also addresses biomarkers predictive of response and resistance to PARP inhibitors.

Key Points:

• Understanding the DNA damage response (DDR) and PARP enzyme interplay is crucial for optimizing cancer therapy.
• Clinical data highlight the effectiveness of PARP inhibitors in mCRPC, with ongoing research into combination therapies.
• Biomarker identification is essential for predicting patient response and overcoming resistance mechanisms to PARP inhibitors.

Conclusions:

• Genomic testing provides valuable insights for selecting patients who may benefit from PARP inhibitors.
• Interpreting genomic results and managing treatment require a multidisciplinary approach.
• PARP inhibitors represent a significant therapeutic advance, necessitating a thorough understanding of their mechanisms, clinical use, and resistance patterns in mCRPC.